Loading…

Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico

Abstract Background Research on hepatitis C virus (HCV) prevalence among non-injecting drug treatment clients in the United States, Europe and Asia indicate substantial differences by place. To date, little or no research on HCV and non-injection drug use (NIDU) has been conducted in Mexico. Methods...

Full description

Saved in:
Bibliographic Details
Published in:Drug and alcohol dependence 2012-06, Vol.123 (1), p.269-272
Main Authors: Campollo, Octavio, Roman, Sonia, Panduro, Arturo, Hernandez, Gabriel, Diaz-Barriga, Lino, Balanzario, Mario C, Cunningham, James K
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Research on hepatitis C virus (HCV) prevalence among non-injecting drug treatment clients in the United States, Europe and Asia indicate substantial differences by place. To date, little or no research on HCV and non-injection drug use (NIDU) has been conducted in Mexico. Methods We examined the prevalence of HCV, hepatitis B virus (HBV), and HIV among non-injecting drug users (NIDUs) in community-based drug treatment ( N = 122) and NIDUs in a prison-based drug treatment program ( N = 30), both located in west central Mexico. Results Among the community clients, prevalence was 4.1% (95% confidence interval [CI]: 1.8–9.2) for HCV, 5.7% for HBV (95% CI: 2.8–11.4), and 1.6% for HIV (95% CI: 0.4–5.8). Among the in-prison clients, prevalence was 40.0% (95% CI: 24.6–57.7) for HCV, 20.0% for HBV (95% CI: 9.5–37.3), and 6.7% for HIV (95% CI: 1.9–21.3). None of the clients were aware of being infected. Conclusion The HCV prevalence found for the NIDU community treatment clients ranks among the lower HCV estimates published for NIDUs in treatment to date. The prevalence found for the in-prison clients ranks among the higher, raising a concern of possible elevated HCV infection among NIDUs in the west central Mexico prison—one compounded by the finding that none of this study's clients knew they were HCV positive.
ISSN:0376-8716
1879-0046
DOI:10.1016/j.drugalcdep.2011.11.009